- Home
- OGS vs AXSM Comparison
OGS vs AXSM Comparison
Compare OGS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGS
- AXSM
- Stock Information
- Founded
- OGS 1906
- AXSM 2012
- Country
- OGS United States
- AXSM United States
- Employees
- OGS N/A
- AXSM N/A
- Industry
- OGS Oil/Gas Transmission
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- OGS Utilities
- AXSM Health Care
- Exchange
- OGS Nasdaq
- AXSM Nasdaq
- Market Cap
- OGS 3.8B
- AXSM 4.2B
- IPO Year
- OGS N/A
- AXSM 2015
- Fundamental
- Price
- OGS $69.88
- AXSM $84.60
- Analyst Decision
- OGS Hold
- AXSM Strong Buy
- Analyst Count
- OGS 6
- AXSM 14
- Target Price
- OGS $70.92
- AXSM $125.54
- AVG Volume (30 Days)
- OGS 392.4K
- AXSM 893.5K
- Earning Date
- OGS 02-19-2025
- AXSM 02-18-2025
- Dividend Yield
- OGS 3.80%
- AXSM N/A
- EPS Growth
- OGS N/A
- AXSM N/A
- EPS
- OGS 3.82
- AXSM N/A
- Revenue
- OGS $2,058,772,000.00
- AXSM $338,457,000.00
- Revenue This Year
- OGS $3.25
- AXSM $44.77
- Revenue Next Year
- OGS $7.51
- AXSM $67.70
- P/E Ratio
- OGS $18.17
- AXSM N/A
- Revenue Growth
- OGS N/A
- AXSM 51.47
- 52 Week Low
- OGS $57.74
- AXSM $64.11
- 52 Week High
- OGS $78.89
- AXSM $105.00
- Technical
- Relative Strength Index (RSI)
- OGS 48.66
- AXSM 43.66
- Support Level
- OGS $66.38
- AXSM $79.19
- Resistance Level
- OGS $69.98
- AXSM $87.53
- Average True Range (ATR)
- OGS 1.27
- AXSM 4.37
- MACD
- OGS 0.23
- AXSM -0.02
- Stochastic Oscillator
- OGS 91.97
- AXSM 61.27
About OGS ONE Gas Inc.
ONE Gas Inc is a regulated natural gas utility company. It is involved in the distribution and sale of natural gas to residential, commercial, industrial, and transportation consumers through its network of pipelines and service lines. Almost all of the company's revenue is derived from natural gas sales in the states of Oklahoma, Kansas, and Texas. The company controls considerable market shares in Oklahoma and Kansas.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.